R&D

The number of CROs in the US quadrupled from 2000 to 2011 to reach more than 3,100, according to Tufts Center for the Study of Drug Development (CSDD). Tufts CSDD examined 3,244 US CROs in 15 major geographic areas, which were thought to represent about three-quarters of US CROs. These firms had total 2011 revenues of about $32.9–$39.5 billion. Tufts CSDD classified market segments as chemistry manufacturing and controls (CMC), staffing-consulting-management services (other), nonclinical research, clinical research and applied research, which comprised 28%, 24%, 21%, 16% and 11% of US CRO revenues in 2011, respectively. Of the firms examined, 39%, 37%, 29%, 20% and 15% provided services related to CMC, nonclinical research, other, clinical research and applied research, respectively. The study found that 69% of CROs were privately held. The mean number of staff was 41, 31, 35, 33 and 21 employees at firms classified as CMC, other, nonclinical research, clinical research and applied research market segments, respectively. Tufts CSDD believes that the worldwide market for R&D services totals $90–$105 billion.

Source: Contract Pharma

< | >